A first-of-its-kind device for pancreatic cancer treatment has been approved by the U.S. Food and Drug Administration.

Novocure (Nasdaq:NVCR) announced that the FDA granted approval for its Optune Pax treatment for advanced pancreatic cancer.

The Swiss biopharmaceutical company’s shares surged in after-hours trading after it said the FDA approved its Optune Pax ...

Learn more about the newly approved wearable treatment that disrupts pancreatic cancer tumor growth while letting patients continue daily life at home.

The FDA approved Optune Pax (Novocure), a first-in-class portable device that delivers tumor-treating fields (TTFields) to the abdomen in adult patients with locally advanced pancreatic cancer, ...

The FDA has approved a first-of-its-kind wearable electrical device — Optune Pax (Novocure) — for patients with locally ...

Moving gemcitabine/nab-paclitaxel to every-other-week dosing decreases infusion visits and may lessen cumulative toxicity, ...

Even before a tumor in the pancreas becomes discernible, an activated cancer gene actively remodels its future environment ...

With this decision, Optune Pax becomes the first new FDA-approved treatment for locally advanced pancreatic cancer in decades. For patients and families navigating this diagnosis, the addition of a ...

Researchers in Spain have developed a therapy protocol that could revolutionize the treatment of pancreatic cancer.

In a recent study, a team of scientists discovered that a treatment using different medications was found to be effective to eliminate pancreatic cancer in mice.

First approved therapy for locally advanced disease in almost three decades ...